Replimune Group (FRA:7R8) Moat Score: 5/10 (As of Jul. 11, 2026)


FRA:7R8 Replimune Group Inc FRA:7R8
32 GF Score
Price €9.22
! 4 Warning Signs
View Full Analysis

What is Replimune Group Moat Score?

Replimune Group FRA:7R8 -3.56% 32 Moat Score is 5 as of Jul. 11, 2026. GuruFocus rates FRA:7R8 with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,395 Biotechnology companies, Replimune Group ranks better than 96.7% on this metric.

Replimune Group has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Replimune Group has Narrow Moat: Replimune Group Inc benefits from valuable intellectual property and strong R&D capabilities in the biotech industry. However, it lacks significant market leadership, brand strength, and durable cost advantages, resulting in a solid but not strong narrow moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Replimune Group might have Narrow Moat - Solid narrow moat.

Replimune Group  (FRA:7R8) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Replimune Group Moat Score Related Terms

FRA:7R8 vs AVTX, KURA, SANA: Moat Score Comparison

For the Biotechnology subindustry, Replimune Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Replimune Group Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Replimune Group's Moat Score distribution charts can be found below:

* The bar in red indicates where Replimune Group's Moat Score falls into.


FRA:7R8
32GF Score
Replimune Group Inc FRA:7R8
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Replimune Group (FRA:7R8) has a Moat Score of 5 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Replimune Group ranks #46 out of 1395 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Replimune Group's Moat Score too high?
Replimune Group's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Replimune Group's value of 5 is 150% above this industry median. Based on the distribution chart, Replimune Group ranks #46 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Replimune Group has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's Moat Score compare to AVTX and KURA?
According to the Biotechnology industry distribution chart, Replimune Group ranks #46 out of 1395 companies for Moat Score. This places Replimune Group in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Replimune Group's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Replimune Group's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Replimune Group's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (FRA:7R8) has a current Moat Score of 5. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Replimune Group's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Replimune Group (FRA:7R8), the current Moat Score is 5 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Replimune Group Business Description

Other Exchanges REPL:USA
Address 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, MA, USA, 01801
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
32GF Score

Get the complete analysis for FRA:7R8

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.22
Price